Cytosorbents Corporation

DB:HQE1 Stock Report

Market Cap: €68.3m

Cytosorbents Valuation

Is HQE1 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of HQE1 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate HQE1's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate HQE1's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for HQE1?

Key metric: As HQE1 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for HQE1. This is calculated by dividing HQE1's market cap by their current revenue.
What is HQE1's PS Ratio?
PS Ratio1.9x
SalesUS$37.74m
Market CapUS$71.63m

Price to Sales Ratio vs Peers

How does HQE1's PS Ratio compare to its peers?

The above table shows the PS ratio for HQE1 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.7x
PUS PULSION Medical Systems
3.8xn/a€136.0m
GME Geratherm Medical
1.1x1.9%€19.3m
SBS Stratec
1.6x6.1%€403.0m
DRW3 Drägerwerk KGaA
0.3x3.3%€954.3m
HQE1 Cytosorbents
1.9x27.8%€71.6m

Price-To-Sales vs Peers: HQE1 is expensive based on its Price-To-Sales Ratio (1.9x) compared to the peer average (1.7x).

Price to Sales Ratio vs Industry

How does HQE1's PS Ratio compare vs other companies in the DE Medical Equipment Industry?

4 CompaniesPrice / SalesEstimated GrowthMarket Cap
DRW3 Drägerwerk KGaA
0.3x3.3%US$1.00b
PHH2 Paul Hartmann
0.4xn/aUS$860.92m
U4W0 Quotient
0.07xn/aUS$2.78m
MF6 MagForce
0.3xn/aUS$404.27k
No more companies available in this PS range
HQE1 1.9xIndustry Avg. 3.8xNo. of Companies4PS01.63.24.86.48+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: HQE1 is good value based on its Price-To-Sales Ratio (1.9x) compared to the European Medical Equipment industry average (3.8x).

Price to Sales Ratio vs Fair Ratio

What is HQE1's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

HQE1 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio1.9x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: HQE1 is good value based on its Price-To-Sales Ratio (1.9x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst HQE1 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€1.22
€4.89
+299.8%
74.8%€9.79€0.98n/a3
Feb ’26€0.93
€4.89
+429.1%
74.8%€9.79€0.98n/a3
Jan ’26€0.87
€4.78
+449.1%
74.8%€9.55€0.96n/a3
Dec ’25€0.83
€4.67
+460.7%
74.8%€9.33€0.93n/a3
Nov ’25€0.91
€4.57
+403.0%
74.8%€9.15€0.91n/a3
Oct ’25€1.32
€4.07
+208.9%
74.5%€9.03€0.90n/a4
Sep ’25€0.89
€4.09
+358.0%
74.5%€9.08€0.91n/a4
Aug ’25€1.08
€4.16
+285.0%
74.5%€9.24€0.92n/a4
Jul ’25€0.66
€2.45
+270.8%
46.8%€3.68€0.92n/a3
Jun ’25€0.78
€2.45
+212.6%
46.8%€3.68€0.92n/a3
May ’25€0.72
€2.46
+240.3%
46.8%€3.69€0.92n/a3
Apr ’25€0.81
€2.45
+201.4%
46.8%€3.68€0.92n/a3
Mar ’25€0.86
€2.45
+185.6%
46.8%€3.68€0.92n/a3
Feb ’25€0.91
€2.45
+170.8%
46.8%€3.68€0.92€0.933
Jan ’25€0.92
€4.08
+341.1%
55.3%€7.25€0.91€0.875
Dec ’24€1.07
€5.15
+380.2%
27.3%€7.35€3.68€0.835
Nov ’24€1.36
€5.61
+311.9%
21.7%€7.48€3.74€0.915
Oct ’24€1.73
€5.61
+224.2%
21.7%€7.48€3.74€1.325
Sep ’24€2.37
€5.94
+150.7%
14.4%€7.31€5.03€0.894
Aug ’24€3.22
€6.08
+89.2%
14.4%€7.49€5.15€1.084
Jul ’24€3.18
€6.08
+91.6%
14.4%€7.49€5.15€0.664
Jun ’24€2.74
€6.08
+122.0%
14.4%€7.49€5.15€0.784
May ’24€2.19
€6.08
+178.4%
14.4%€7.49€5.15€0.724
Apr ’24€3.09
€6.08
+96.9%
14.4%€7.49€5.15€0.814
Mar ’24€2.98
€6.08
+104.0%
14.4%€7.49€5.15€0.864
Feb ’24€2.64
€6.69
+153.6%
15.4%€8.03€5.52€0.913
Analyst Price Target
Consensus Narrative from 3 Analysts
€4.71
Fair Value
74.0% undervalued intrinsic discount
3
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/14 02:53
End of Day Share Price 2025/02/14 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytosorbents Corporation is covered by 9 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jonathan AschoffBrean Capital
Jason KolbertD. Boral Capital LLC.
Swayampakula RamakanthH.C. Wainwright & Co.